Very happy to have been able to contribute to this amazing story! Check out the paper at Nature Communications and the 🧵 by @nckvalerie.bsky.social below 👇. We believe #CeTeam will be an invaluable tool for #drugdiscovery and #targetvalidation in #cells
🔗: www.nature.com/articles/s41...
🔗: www.nature.com/articles/s41...
December 11, 2024 at 7:20 PM
Very happy to have been able to contribute to this amazing story! Check out the paper at Nature Communications and the 🧵 by @nckvalerie.bsky.social below 👇. We believe #CeTeam will be an invaluable tool for #drugdiscovery and #targetvalidation in #cells
🔗: www.nature.com/articles/s41...
🔗: www.nature.com/articles/s41...
Good timing for a first Bluesky post! 🦋
I'm thrilled to share that our BioRxiv preprint on #CeTEAM has now been published in Nature Communications!
🔗: www.nature.com/articles/s41...
A short 🧵 1/x 👇
I'm thrilled to share that our BioRxiv preprint on #CeTEAM has now been published in Nature Communications!
🔗: www.nature.com/articles/s41...
A short 🧵 1/x 👇
Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM - Nature Communications
Cellular target engagement technologies enable quantification of intracellular drug binding, but the simultaneous assessment of drug-associated phenotypes is challenging. Here, the authors develop CeT...
www.nature.com
December 11, 2024 at 12:04 AM
Good timing for a first Bluesky post! 🦋
I'm thrilled to share that our BioRxiv preprint on #CeTEAM has now been published in Nature Communications!
🔗: www.nature.com/articles/s41...
A short 🧵 1/x 👇
I'm thrilled to share that our BioRxiv preprint on #CeTEAM has now been published in Nature Communications!
🔗: www.nature.com/articles/s41...
A short 🧵 1/x 👇
Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM https://www.biorxiv.org/content/10.1101/2024.08.09.607390v1
Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM https://www.biorxiv.org/content/10.1101/2024.08.09.607390v1
PARP inhibitors (PARPi) predominantly targeting PARP1 and PARP2 have revolutionized cancer therapy b
www.biorxiv.org
August 10, 2024 at 7:45 PM
Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM https://www.biorxiv.org/content/10.1101/2024.08.09.607390v1
RRIDs were included in this Journal of Biological Chemistry paper. Thanks for making your methods matter! #accelerateopenscience #ReproducibleResearch #RRID
Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells
doi.org
May 25, 2025 at 7:00 AM
RRIDs were included in this Journal of Biological Chemistry paper. Thanks for making your methods matter! #accelerateopenscience #ReproducibleResearch #RRID
Happy to share that this work out of @ki.se and @scilifelab.se on PARPi selectivity profiling in cells using duplexed PARP1/2 CeTEAM biosensors is now in press at JBC!👇
www.jbc.org/article/S002...
Short 🧵: 1/n
www.jbc.org/article/S002...
Short 🧵: 1/n
Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) targeting PARP1 and PARP2 have
revolutionized cancer therapy by selectively killing cancer cells with defective DNA
repair. However, achieving PA...
www.jbc.org
March 7, 2025 at 3:30 PM
Happy to share that this work out of @ki.se and @scilifelab.se on PARPi selectivity profiling in cells using duplexed PARP1/2 CeTEAM biosensors is now in press at JBC!👇
www.jbc.org/article/S002...
Short 🧵: 1/n
www.jbc.org/article/S002...
Short 🧵: 1/n
Congrats to first author, Seher Alam, and thanks to all students and collaborators!
We're grateful for support from @scilifelab.se, @novonordisk.bsky.social, and Cancer Research KI, as well as fellowships from Barncancerfonden and Cancerfonden.
Fin
#TPD #PROTAC #CeTEAM #NUDT5
We're grateful for support from @scilifelab.se, @novonordisk.bsky.social, and Cancer Research KI, as well as fellowships from Barncancerfonden and Cancerfonden.
Fin
#TPD #PROTAC #CeTEAM #NUDT5
June 25, 2025 at 10:21 AM
Congrats to first author, Seher Alam, and thanks to all students and collaborators!
We're grateful for support from @scilifelab.se, @novonordisk.bsky.social, and Cancer Research KI, as well as fellowships from Barncancerfonden and Cancerfonden.
Fin
#TPD #PROTAC #CeTEAM #NUDT5
We're grateful for support from @scilifelab.se, @novonordisk.bsky.social, and Cancer Research KI, as well as fellowships from Barncancerfonden and Cancerfonden.
Fin
#TPD #PROTAC #CeTEAM #NUDT5
Parts 1-2/2 — EFTA02590513.jpg
#epsteinweb #efta02590513
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
#epsteinweb #efta02590513
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
April 14, 2026 at 11:27 PM
Parts 1-2/2 — EFTA02590513.jpg
#epsteinweb #efta02590513
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
#epsteinweb #efta02590513
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
• CeTEAM stability-dependent sensors for CRBN and VHL to monitor E3 ligase binding (and ternary complex "hook" effects) ✅ 👀
Oh yeah, and a functional VHL-directed NUDT5 PROTAC, DDD2, which complements a CRBN variant reported by @chembiohub.bsky.social.
More on NUDT5 coming soon, stay tuned!
3/4
Oh yeah, and a functional VHL-directed NUDT5 PROTAC, DDD2, which complements a CRBN variant reported by @chembiohub.bsky.social.
More on NUDT5 coming soon, stay tuned!
3/4
June 25, 2025 at 10:21 AM
• CeTEAM stability-dependent sensors for CRBN and VHL to monitor E3 ligase binding (and ternary complex "hook" effects) ✅ 👀
Oh yeah, and a functional VHL-directed NUDT5 PROTAC, DDD2, which complements a CRBN variant reported by @chembiohub.bsky.social.
More on NUDT5 coming soon, stay tuned!
3/4
Oh yeah, and a functional VHL-directed NUDT5 PROTAC, DDD2, which complements a CRBN variant reported by @chembiohub.bsky.social.
More on NUDT5 coming soon, stay tuned!
3/4
This direct-to-cell CeTEAM selectivity assay should facilitate the discovery of truly selective PARPi (as well as triaging of PARP trapping tendencies!).
Congrats to all authors, esp. Maria Pires and Seher Alam!
Funding: Cancerfonden and Barncancerfonden 🙏
#PARP
#selectivity
#CeTEAM
3/3
Congrats to all authors, esp. Maria Pires and Seher Alam!
Funding: Cancerfonden and Barncancerfonden 🙏
#PARP
#selectivity
#CeTEAM
3/3
March 7, 2025 at 3:30 PM
This direct-to-cell CeTEAM selectivity assay should facilitate the discovery of truly selective PARPi (as well as triaging of PARP trapping tendencies!).
Congrats to all authors, esp. Maria Pires and Seher Alam!
Funding: Cancerfonden and Barncancerfonden 🙏
#PARP
#selectivity
#CeTEAM
3/3
Congrats to all authors, esp. Maria Pires and Seher Alam!
Funding: Cancerfonden and Barncancerfonden 🙏
#PARP
#selectivity
#CeTEAM
3/3
Also be sure to check out our follow-up preprint where we comprehensively profile PARP inhibitor selectivity in cells using duplexed PARP1 and PARP2 CeTEAM drug biosensors.
🔗: www.biorxiv.org/content/10.1...
🚨 Stay tuned for more upcoming CeTEAM-related science! 🚨
7/7
🔗: www.biorxiv.org/content/10.1...
🚨 Stay tuned for more upcoming CeTEAM-related science! 🚨
7/7
Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity
PARP inhibitors (PARPi) predominantly targeting PARP1 and PARP2 have revolutionized cancer therapy by selectively killing cancer cells with defective DNA repair. However, achieving PARP1 or PARP2-sele...
www.biorxiv.org
December 11, 2024 at 12:04 AM
Also be sure to check out our follow-up preprint where we comprehensively profile PARP inhibitor selectivity in cells using duplexed PARP1 and PARP2 CeTEAM drug biosensors.
🔗: www.biorxiv.org/content/10.1...
🚨 Stay tuned for more upcoming CeTEAM-related science! 🚨
7/7
🔗: www.biorxiv.org/content/10.1...
🚨 Stay tuned for more upcoming CeTEAM-related science! 🚨
7/7
Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM https://www.biorxiv.org/content/10.1101/2024.08.09.607390v1
Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM https://www.biorxiv.org/content/10.1101/2024.08.09.607390v1
PARP inhibitors (PARPi) predominantly targeting PARP1 and PARP2 have revolutionized cancer therapy b
www.biorxiv.org
August 10, 2024 at 7:45 PM
Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM https://www.biorxiv.org/content/10.1101/2024.08.09.607390v1